Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-COVID vaccine
- Development stage
- Unknown
- Lead developer
- Advagene
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
LT-COVID is an intranasal protein subunit vaccine candidate developed by Advagene Biopharma for the prevention of COVID-19. The vaccine utilizes Advagene's proprietary LTh(αK) adjuvant platform, which consists of a detoxified version of the *Escherichia coli* heat-labile enterotoxin. This adjuvant acts as a mucosal immunomodulator, inducing the expression of type I and III interferons from mucosal epithelial cells to elicit both robust mucosal (IgA) and systemic (IgG) immune responses against SARS-CoV-2. By delivering the vaccine via a nasal spray, it aims to establish a first line of defense at the respiratory mucosa, the primary site of viral entry for the SARS-CoV-2 virus.
- Other names
- 鼻噴型新冠肺炎疫苗nasal spray COVID-19 vaccineAdvagene nasal COVID-19 vaccine
02
Targets
GM1 (GM1 ganglioside)
Beyond the preview
Go deeper on LT-COVID vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-COVID vaccine.